Physician profile
Eric G Tepper
NPI 1891798146
$137,623.50
in general payments reported to CMS, 2019-2025
66 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,642 · 2020: $2,237 · 2021: $11K · 2022: $20K · 2023: $44K · 2024: $35K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $75K · Travel and Lodging: $16K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75,460.00 |
| Travel and Lodging | $16,148.80 |
| Food and Beverage | $10,728.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $121,565.40 | 2019-2025 | Spravato, Xarelto |
| Abbvie INC. | $2,644.34 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Lilly USA, LLC | $1,524.85 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $1,313.80 | 2019-2025 | Evenity, Otezla, Repatha |
| Allergan, INC. | $1,085.32 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $889.16 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $843.18 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $774.57 | 2019-2025 | Jardiance, Ofev |
| Teva Pharmaceuticals USA, INC. | $673.94 | 2019-2025 | Ajovy, Austedo Xr |
| Glaxosmithkline, LLC. | $598.22 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $526.60 | 2023-2025 | Auvelity, Sunosi |
| Indivior INC. | $459.61 | 2019-2025 | Sublocade |
| Corcept Therapeutics | $451.61 | 2024-2025 | Korlym |
| Radius Health, INC. | $444.62 | 2020-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $438.55 | 2019-2025 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Tepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.